「2025」の検索結果

Expert guidance across solar physics, planetary science, stellar evolution, cosmology, and observational techniques with 2025 mission data

日本語の概要は準備中です。原文の説明を表示しています。

Advanced vulnerability analysis principles. OWASP 2025, Supply Chain Security, attack surface mapping, risk prioritization.

日本語の概要は準備中です。原文の説明を表示しています。

Cycle horaire du coordinateur adjoint myia-po-2025:CoursIA-2. Réduit la file, répond aux ASK CoursIA-2, publie des preflights COMMENTED et dispatche les lanes CoursIA-2, sans merge ni arbitrage réservé à ai-01.

日本語の概要は準備中です。原文の説明を表示しています。

Arm proactive 5-hour usage protection for long Claude Code sessions (batch, subagents, high window % at start). Daemon reads account-level 5-hour window usage (not per-session). User types /usage-guard at session start. Re-arm every sitting. If user mentions usage-guard by name, read this file and run arm.sh.

日本語の概要は準備中です。原文の説明を表示しています。

Designs and analyzes in vivo CRISPR screens in animal tumor models, organoids, and immune-cell adoptive transfers. Covers bottleneck math (250x cells/sgRNA requires ~25M cells implanted; impossible for most syngeneic models, forcing focused libraries), focused library design (Manguso 2017 Nature 547:413 immune screen; Chen 2015 tumor screens), CRISPR-StAR intrinsic-control screening (Uijttewaal 2025 Nat Biotechnol 43:1848), clonal-dynamics-limited detection, tumor-explant DNA recovery, syngeneic vs xenograft vs PDX considerations, and the relationship to downstream MAGeCK / drugZ analysis. Use when designing in vivo CRISPR screens for tumor / immune / metastasis biology, choosing focused vs genome-wide for animal models, addressing bottleneck-induced clonal collapse, picking the syngeneic / xenograft / PDX model, integrating in vivo with in vitro results, or applying CRISPR-StAR for animal experiments.

日本語の概要は準備中です。原文の説明を表示しています。

Tests genotype-environment associations and identifies adaptive loci while correcting for the four-confound landscape (structure, demography, background selection, sampling design) using LFMM2 with mandatory K via sNMF cross-entropy elbow (LEA 3), BayPass Core/AUX/C2/IS with Omega covariance matrix, RDA / pRDA for polygenic adaptation (Forester 2018; requires imputed genotypes), OutFLANK with trimmed FST null, pcadapt, gradient forests (Ellis-Smith-Pitcher 2012, NOT mis-cited Ellis-Manel), Capblancq & Forester 2021 RDA Swiss-army-knife, genomic-offset prediction with Lind & Lotterhos 2025 three-regime caveat, Lotterhos-Whitlock sampling optima, Wang & Bradburd 2014 IBD vs IBE, and Circuitscape + ResistanceGA. Use when identifying adaptive loci across gradients, choosing K for LFMM2, deciding among GEA methods, predicting maladaptation with the novel-environment caveat, distinguishing IBD vs IBE, or optimizing sampling design.

日本語の概要は準備中です。原文の説明を表示しています。

Detects differential alternative splicing between conditions using rMATS-turbo (binomial LRT on junction counts), leafcutter (Dirichlet-multinomial GLM on intron clusters), MAJIQ V3 deltapsi/HET (Bayesian posterior on LSVs), SUPPA2 (empirical-null on TPM-derived PSI), or Shiba (junction-imbalance-corrected, 2025 SOTA at low coverage). Reports FDR-corrected significance and delta PSI effect sizes. Tools differ in statistical model, annotation dependence, calibration regime, and replicate-count requirements. Use when comparing splicing patterns between treatment groups, tissues, or disease states.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 16a.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes CUT&RUN (Skene Henikoff 2017) and CUT&Tag (Kaya-Okur 2019) chromatin profiling data. Handles SEACR vs MACS2 peak calling (with the btaf375 2025 benchmark guidance), pA-MNase vs pA-Tn5 vs pAG-Tn5 chimera differences, E. coli spike-in carryover normalization, IgG-only control logic (no input), characteristic fragment-size signatures (25-75 bp for CUT&Tag), and lower depth requirements (5M reads typical vs 25M for ChIP). Use when calling peaks from CUT&RUN/CUT&Tag, scaling by E. coli spike-in carryover, choosing SEACR norm mode, or comparing CUT&RUN/Tag results to traditional ChIP.

日本語の概要は準備中です。原文の説明を表示しています。

Applies ACMG/AMP 2015 framework with ClinGen SVI specifications, Tavtigian 2018/2020 Bayesian point system, Abou Tayoun 2018 PVS1 decision tree, Pejaver 2022 and Bergquist 2025 calibrated PP3/BP4 thresholds for REVEL/BayesDel/AlphaMissense, Brnich 2020 PS3/BS3 OddsPath, Walker 2023 SpliceAI splicing framework, and AMP/ASCO/CAP 2017 tumor tiers. Use when classifying germline variants P / LP / VUS / LB / B, applying VCEP-specific CSpec rules, computing Whiffin BS1, or assigning cancer Tier I-IV per Li 2017.

日本語の概要は準備中です。原文の説明を表示しています。

Auri: assistente de voz inteligente (Alexa + Claude claude-opus-4-20250805). Visao do produto, persona Vitoria Neural, stack AWS, modelo Free/Pro/Business/Enterprise, roadmap 4 fases, GTM, north star WAC e analise competitiva.

日本語の概要は準備中です。原文の説明を表示しています。

Audits and designs iOS/macOS/watchOS/visionOS interfaces against the Apple Human Interface Guidelines, including the Liquid Glass design language (announced WWDC25, shipped with iOS 26/macOS Tahoe, Sept 2025). Use when reviewing an Apple-platform mockup or app for HIG compliance, checking contrast or tap-target sizes, or designing native-feeling Apple UI (e.g., 'audit my iOS app against the HIG', 'is this text readable on Liquid Glass?').

日本語の概要は準備中です。原文の説明を表示しています。

Expert in turning data visualizations into compelling video and animation content for social media and marketing. Activate on: data commercial, animated chart, data storytelling video, chart animation, Remotion data video, Motion Canvas, Flourish animation, D3 animation, data viz social media, dashboard recording, data narrative video. NOT for: static data visualization (use data-viz-2025), general video editing (use video-processing-editing), full video production pipeline (use ai-video-production-master).

日本語の概要は準備中です。原文の説明を表示しています。

license: Apache-2.0 NOT for unrelated tasks outside this domain.

日本語の概要は準備中です。原文の説明を表示しています。

Select the right pharmacologic agent for a child aged 12+ with obesity using the CMAJ 2025 guideline — choosing between GLP-1 receptor agonists, metformin, or orlistat with monitoring guidance. Trigger when a clinician asks which medication to use for pediatric obesity, whether to start semaglutide or metformin in a child, or how to manage obesity pharmacologically in adolescents.

日本語の概要は準備中です。原文の説明を表示しています。

Guide a non-stigmatising pediatric obesity consultation using the 5As framework (Ask, Assess, Advise, Agree, Assist) and 4Ms assessment (Metabolic, Mechanical, Mental Health, Social Milieu), based on the CMAJ 2025 guideline. Trigger when a clinician asks how to approach a weight conversation with a child or family, how to use the 5As for obesity, how to assess a child with obesity, or how to conduct a non-judgmental obesity visit.

日本語の概要は準備中です。原文の説明を表示しています。

Screen a child aged 13+ with obesity for eligibility for bariatric surgery (laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass) using the CMAJ 2025 guideline. Trigger when a clinician asks whether a child qualifies for weight loss surgery, bariatric surgery in adolescents, sleeve gastrectomy in a teenager, or when to refer for surgical management of pediatric obesity.

日本語の概要は準備中です。原文の説明を表示しています。

Decide whether a kidney from a brain-dead deceased donor (DBD) with diabetes mellitus and/or hypertension is suitable for transplantation, using the ISOT 2025 Delphi consensus and Table 4 eligibility checklist. Trigger when a clinician asks "can I use a kidney from a diabetic deceased donor", "is this DBD with HTN/DM acceptable", "ECD donor with diabetes — accept or decline", "DBD eligibility for hypertensive donor", or shares a deceased donor with diabetes or hypertension and needs an accept/borderline/decline decision.

日本語の概要は準備中です。原文の説明を表示しています。

Select the right treatment tier for a child with obesity — behavioural, pharmacologic, or surgical — using the CMAJ 2025 pediatric obesity guideline. Trigger when a clinician asks what to do for a child with obesity, which intervention to start, whether to escalate treatment, or when to consider medication or surgery for pediatric obesity.

日本語の概要は準備中です。原文の説明を表示しています。

Híbrido RNN+Transformer com inferência O(n). Tempo linear, contexto infinito, sem cache KV. Treina como GPT (paralelo), infere como RNN (sequencial). Projeto Linux Foundation AI. Produção em Windows, Office, NeMo. RWKV-7 (março de 2025). Modelos até 14B parâmetros.

日本語の概要は準備中です。原文の説明を表示しています。

[Code Quality] Use when you need to perform a security review or audit on any scope — application code (OWASP Top 10 2025), secrets exposure, dependency/supply-chain malware, third-party repository vetting before install, infrastructure/config, CI/CD pipeline, AI-agent risks, and host/VPS compromise detection.

日本語の概要は準備中です。原文の説明を表示しています。

Auri: assistente de voz inteligente (Alexa + Claude claude-opus-4-20250805). Visao do produto, persona Vitoria Neural, stack AWS, modelo Free/Pro/Business/Enterprise, roadmap 4 fases, GTM, north star WAC e analise competitiva.

日本語の概要は準備中です。原文の説明を表示しています。

Detects prompt injection attacks targeting LLM-based applications using a multi-layered defense combining regex pattern matching for known attack signatures, heuristic scoring for structural anomalies, and transformer-based classification with DeBERTa models. The detector analyzes user inputs before they reach the LLM, flagging direct injections (system prompt overrides, role-play escapes, instruction hijacking) and indirect injections (encoded payloads, multi-language obfuscation, delimiter-based escapes). Based on the OWASP LLM Top 10 (LLM01:2025 Prompt Injection) and Simon Willison's prompt injection taxonomy. Activates for requests involving prompt injection detection, LLM input sanitization, AI security scanning, or prompt attack classification.

日本語の概要は準備中です。原文の説明を表示しています。